Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$18.40 USD
-0.07 (-0.38%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $18.32 -0.08 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.40 USD
-0.07 (-0.38%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $18.32 -0.08 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 10.66% and 74.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for August 23rd
by Zacks Equity Research
JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023.
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
by Zacks Equity Research
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
by Zacks Equity Research
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
by Zacks Equity Research
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
by Zacks Equity Research
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
New Strong Buy Stocks for August 16th
by Zacks Equity Research
GM, IBN, PIRS, GPI and MBWM have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2023.
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
by Zacks Equity Research
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
by Zacks Equity Research
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -28.57% and 70.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Misses Q4 Earnings Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of -5.41% and 2.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 18.75% and 19.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.